Silencing of EGLN1 could activate the downstream pathway of hypoxia-inducible factor 1α (HIF1α) and Wnt/β-catenin, thus increasing the expression of cancer stem cell (CSCs) associated genes 9,10. This evidence concerns the gene EGLN1 and cancer.